{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-003537","form_type":"8-K/A","ticker":"TSHA","cik":"0001806310","company_name":"Taysha Gene Therapies, Inc.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.668331+00:00","generated_at":"2026-06-20T18:56:09.850586+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Taysha Gene Therapies: CEO salary $600K, President $565K; equity grants of 1.1M and 790K options","bullets":["Sean Nolan appointed CEO effective Dec 16, 2022; base salary $600K, annual target bonus 60% of base.","Nolan receives option for 1,106,131 shares; 25% vests Dec 16, 2023, remainder monthly over 36 months.","Sukumar Nagendran appointed President & Head of R&D; base $565K, bonus target 50%, option for 790,093 shares with same vesting.","Severance: Nolan gets 18 months salary + 150% target bonus; Nagendran 15 months + 100% target bonus upon qualifying termination."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-003537","json":"https://secwatch.observer/filing/0001193125-23-003537.json","markdown":"https://secwatch.observer/filing/0001193125-23-003537.md","text":"https://secwatch.observer/filing/0001193125-23-003537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/0001193125-23-003537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/d410825d8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:56:09.850586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"30eabb8221","claim":"Sukumar Nagendran was appointed as President and Head of Research and Development at Taysha Gene Therapies, Inc..","evidence_excerpt":"the Board appointed Dr. Sukumar Nagendran as the Company’s President and Head of Research and Development, effective December 16, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/0001193125-23-003537-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Head of Research and Development"}],"fact_type":"executive_change"},{"claim_id":"ab1fdaaac1","claim":"Sean Nolan was appointed as Chief Executive Officer at Taysha Gene Therapies, Inc..","evidence_excerpt":"the Company’s board of directors (the “ Board ”) appointed Mr. Nolan as the Company’s Chief Executive Officer, effective on December 16, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1806310/000119312523003537/0001193125-23-003537-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}